FY2029 Earnings Forecast for BriaCell Therapeutics Corp. Issued By HC Wainwright (NASDAQ:BCTX)

BriaCell Therapeutics Corp. (NASDAQ:BCTX) – Research analysts at HC Wainwright issued their FY2029 earnings estimates for shares of BriaCell Therapeutics in a research report issued on Thursday, September 19th. HC Wainwright analyst E. Bodnar anticipates that the company will post earnings of ($0.05) per share for the year. HC Wainwright has a “Buy” rating and a $15.00 price objective on the stock. The consensus estimate for BriaCell Therapeutics’ current full-year earnings is ($1.39) per share.

BriaCell Therapeutics Stock Up 15.1 %

Shares of BriaCell Therapeutics stock opened at $0.60 on Friday. The stock has a market cap of $11.01 million, a PE ratio of -0.48 and a beta of 1.31. BriaCell Therapeutics has a 12 month low of $0.46 and a 12 month high of $6.36. The business has a fifty day simple moving average of $0.71 and a 200-day simple moving average of $1.55.

Institutional Investors Weigh In On BriaCell Therapeutics

An institutional investor recently raised its position in BriaCell Therapeutics stock. K.J. Harrison & Partners Inc lifted its stake in BriaCell Therapeutics Corp. (NASDAQ:BCTX) by 7.8% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 87,044 shares of the company’s stock after purchasing an additional 6,329 shares during the quarter. K.J. Harrison & Partners Inc owned 0.54% of BriaCell Therapeutics worth $249,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 15.42% of the stock is owned by hedge funds and other institutional investors.

BriaCell Therapeutics Company Profile

BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor. It is also developing personalized off-the-shelf treatments for breast cancer, prostate cancer, and other cancers.